About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

BofA Securities 2025 Healthcare Conference May 13, 2025 1:40 PM ETCompany ParticipantsJohn Reed - Executive Vice ...

Software engineering: To create machine learning systems, you’ll need an understanding of software engineering. Machine learning algorithms and frameworks: Algorithms and frameworks are tools that you ...

Nightview Capital discusses automation, AI, electrification and trends shaping the future. Click here to read their latest ...

Q1 2025 pharma services revenue of $2.1 million, at 62% gross margin; Three of the top 10 U.S. transplant centers expected to participate in clinical trial; Ten globally leading t ...

Imperial Brands Plc, parent company of Greensboro's ITG Brands Plc, announced Wednesday that Stefan Bomhard plans to retire as chief executive on Oct. 1. Bomhard, who has served as chief executive ...

Q1 2025 pharma services revenue of $2.1 million, at 62% gross marginThree of the top 10 U.S. transplant centers expected to participate in clinical trialTen globally leading transplant hospitals are ...

Q1 2025 Earnings Call Transcript May 13, 2025 Biodesix, Inc. reports earnings inline with expectations. Reported EPS is ...

In our 2025 data review, we found that approximately 10% of the families had at least one substantiation, including ...

Table 1 shows the transitions between 2014 and 2025 across the 186 ... Because of old age, she is currently renting out the ...

Skyharbour Resources Ltd.  ("Skyharbour" or the "Company"), is pleased to announce that its joint-venture partner, Orano Canada Inc. ("Orano"), will commence a large-scale diamond drilling program at ...

The Reduced Risk Products market grows due to health awareness, regulatory support, and rising demand for safer nicotine alternatives, says Fact.MR. ROCKVILLE, MD, UNITED STATES, May 15, 2025 ...